127 results about "Immune disorder" patented technology

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The present invention relates generally to compositions, formulations, and methods for immunotherapy and drug delivery, including the treatment of eye diseases such as dry eye disease (DED). In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells (MSC-Exos) and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and / or siRNA. In specific embodiments, the exosomes, and / or one or more biological compounds derived from the exosomes, may be provided to an individual in need thereof, including as part of one or more compositions containing mesenchymal stem cells (MSCs). The individual in need thereof may be an individual having a medical disorder such as DED, immune disorders, cancer, and other disorders. Therefore, the compositions containing MSCs can be used for topical application to the eye. The compositions can contain MSCs, MSC-Exos, one or more MSC-derived biological compounds (e.g., growth factors, proteins, etc.).

Provided herein are methods for preparing and characterizing SARS-co2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections and immune disorders. Also, provided are compositions and methods for generating immune cells expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARs-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

Single-nucleotide variants (SNVs) in key T cell genes can drive clinical pathologies and could be repurposed to improve cellular cancer immunotherapies. Here, we perform massively parallel base editing screens to generate thousands of variants at gene loci annotated with known or potential clinical significance. We discover a broad landscape of putative gain- (GOF) and loss-of-function (LOF) mutations, including in PIK3CD and its regulatory subunit PIK3R1, LCK, SOS, AKT1, and RHOA. Base editing of PIK3CD and PIK3R1 variants in T cells with an engineered T cell receptor specific against a melanoma epitope or in different generations of CD19 chimeric antigen receptor T (CAR-T) cells demonstrates that discovered GOF variants, but not LOF or silent mutation controls, enhanced signaling, cytokine production and lysis of cognate melanoma and leukemia cell models, respectively. Additionally, we show that generations of CD19 CAR-T cells engineered with PIK3CD GOF mutations demonstrate enhanced antigen-specific signaling, cytokine production, and leukemia cell killing, including when benchmarked against other recent strategies.

The present invention relates to an oligonucleotide comprising from 10 to 25 nucleotides wherein at least one of said nucleotides is modified, and the oligonucleotide hybridizes with the pre-mRNA of the neurociliin 1 (NRP1, CD304) of SEQ ID NO. 366 (GRCh38p13Chr 1033177492-33336262-1) or with the mRNA of the NRP1 of SEQ ID NO. 367 (RefSeq ID NM003873.6). The invention also relates to a pharmaceutical composition comprising the oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating cancer, ophthalmic disease, autoimmune disorder and / or immune disorder.

Disclosed herein are boronated amino acid compositions comprising tyrosine derivatives TC220 and TC221 and improved methods of making TC220 and TC221. Thus, the TC220 and / or TC221 can be expanded to commercial scale and administered to patients as neutron trapping agents, and methods of treating cancer, immune disorders, and other diseases by utilizing a neutron capture therapy pattern are provided.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function and for treating repeat expansion disorders comprising genetic, degenerative, neurological and cellular diseases, including immune disorders. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first population of a cellular protein or therapeutic target with minimal or negligible effect on the activity of at least a second population of the cellular protein or therapeutic target.

The present invention relates to the field of biomedicine, and more specifically, to a humanized anti-human PD-L1 antibody or antigen-binding fragment thereof and its use. The antibody or antigen-binding fragment thereof of the present invention has high affinity and strong binding specificity for PD-L1, effectively blocks the binding of PD-L1 to PD-1 and CD80, stimulates cytokine production, and exhibits significant anti-tumor effects. It can be used alone or in combination with other agents to prevent or treat immune disorders or tumor-related diseases.

The invention discloses a rhamnosus lactobacillus QS001 and a use thereof for preparing an intestinal probiotic preparation, wherein the rhamnosus lactobacillus QS001 is classified and named as rhamnosus lactobacillus Lacticaseibacillus rhamnosus , deposited in the General Microbiology Center of China Microorganism Culture Collection Committee, with the deposit number CGMCC No.29275. The rhamnosus casei bacteria QS001 is used in the preparation of intestinal probiotic preparations. The active ingredients of the probiotic preparations include the bacteria of the above-mentioned rhamnosus casei bacteria QS001. The rhamnosus casei bacteria QS001 is also used in the preparation of immune disorder regulators, drugs for increasing the concentration of anti-inflammatory cytokines and / or reducing the concentration of pro-inflammatory cytokines in colon tissue, and has the advantage of alleviating or treating inflammatory bowel disease and regulating immune disorders.

Tolerogenic liposome-based compositions and uses thereof for treating immune disorders. The compositions include two populations of liposomes. The first population of liposomes has a size in the range from 2 to 200 nm, and the second population of liposomes has a size in the range from 500 to 2000 nm. The liposomes of the first and second populations carry one or more antigens. The liposomal membrane of each liposome in the first and second liposome populations include phosphatidylserine in an amount ranging from 20 to 60% by weight with respect to the total composition of the liposome's membrane.

The invention discloses a traditional Chinese medicine composition for treating sepsis as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from 1-15 parts of sulfur, 3-25 parts of calamitas urinae hominis, 1-20 parts of wine-treated rhubarb, 10-30 parts of fructus cannabis, 10-50 parts of radix bupleuri, 5-30 parts of scutellaria baicalensis, 5-25 parts of folium isatidis, 5-25 parts of peach kernels, 5-30 parts of salvia miltiorrhiza, 5-30 parts of angelica sinensis, 5-30 parts of sophora flower charcoal, 5-25 parts of fructus gardeniae praeparatus and 5-60 parts of wine-treated fructus corni. According to the invention, through a combined mode of'monarch drug targeted oral administration and synergistic decoction of minister, assistant and guide drugs', the whole-course intervention of'upstream inhibition, midstream blocking and downstream regulation 'on sepsis immune disorder can be realized, meanwhile, the functions of warming yang, dispelling cold, cooling blood and detoxifying are taken into account, and the pro-inflammatory / anti-inflammatory balance is successfully recovered to a physiological state; the action mode is superior to that of a traditional single anti-inflammatory strategy and a traditional Chinese medicine application mode of whole-prescription decoction. In a standard animal model, the traditional Chinese medicine composition definitely shows the dose-dependent extremely remarkable effects of anti-inflammation, immunoregulation, multi-organ protection and overall condition improvement, the curative effect of a high-dose group of the traditional Chinese medicine composition is equivalent to that of a classic potent medicine, and the traditional Chinese medicine composition has more advantages in the aspects of recovering immune homeostasis, warming yang and strengthening the body resistance.

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

To provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and neutron capture therapy (NCT).SOLUTION: Disclosed herein are borylated amino acid ("BAA") compositions and methods of making BAAs. Accordingly, BAAs can be administered to patients as neutron capture agents and can provide methods of treating cancer, immune disorders, and other diseases by utilizing neutron capture therapy modalities. The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the present invention relates to borylated amino acid ("BAA") or ("BAAs") compositions that can be used as a vehicle for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases.SELECTED DRAWING: None

To provide formulated and / or co-formulated liposome compositions containing IDO antagonist prodrugs useful in treatment of cancer and methods thereof.SOLUTION: Formulated and / or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and / or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.SELECTED DRAWING: None

The invention provides an anti-CXCR6 antibody and an application thereof. The anti-CXCR6 antibody provided by the invention can bind to CXCR6 with high affinity and high specificity, has species cross binding activity of human and monkey CXCR6, and is a CXCR6-targeted clearance antibody, so that the anti-CXCR6 antibody has great potential to be used for treating inflammation or immune disorder diseases; moreover, compared with the existing CXCR6 antibody, the anti-CXCR6 antibody provided by the invention has obviously lower cell nonspecific binding, so that the anti-CXCR6 antibody provided by the invention has lower off-target toxicity and better safety.

The development of new immunoregulatory small molecules represents a significant advance in immunotherapy. Provided herein are compounds, such as compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits that may be used in immunotherapy. The compounds provided herein are responsible for immunomodulatory signaling through the TLR2 receptor and are therefore useful for the treatment and / or prevention of various diseases (e.g., metabolic diseases, inflammatory diseases, immune disorders, or proliferative diseases).

The invention provides a series of GMPS enzyme inhibitors. The invention includes potent GMPS inhibitors that specifically and covalently bind to GMPS, exhibit broad anti-cancer activity, block the infection efficiency of viruses, and have the potentials to suppress undesired immune responses. These novel inhibitors of GMPS, and their derivatives, have tremendous potentials to be used as therapeutic agents for the treatment of cancers, viral infection and immune disorders.

This invention discloses a class of indole derivatives containing or without heteroatoms (such as nitrogen heteroatoms) and their pharmaceutical compositions that can be used as PI3Kδ kinase inhibitors, and can be used to treat diseases, conditions or symptoms related to PI3Kδ inhibition, including immune disorders, cancer and cardiovascular diseases.

Disclosed herein are 3,4-didehydro- and 3′-deoxy-3,4-didehydro-compounds and pharmaceutical compositions thereof. Methods of use of these pharmaceutical compositions include those for treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SAR-CoV-2, EBV, BKV, JCV and HCMV.

The present invention relates to compounds of formula (I) and pharmaceutically acceptable compositions thereof useful as toll-like receptor 7 / 8 (TLR7 / 8) antagonists.SOLUTION: In Formula (I), ring A is aryl or heteroaryl; ring B is aryl or heteroaryl; and X is C (R4) 2, O, NR4, S, S (R4), or S (R4) 2.SELECTED DRAWING: None

The invention provides a method for preparing gamma delta T cells and application of the gamma delta T cells. The gamma delta T cells are useful for the treatment of various cancers, infectious diseases and immune disorders. Also provided are methods for expanding a population of gamma delta T cells to a therapeutically effective amount. The gamma delta T cells may be administered to a subject having any MHC haplotype.

The present invention relates to pyrazolyl-pyrimidine derivatives, methods for their preparation, pharmaceutical compositions comprising them, and their use as therapeutic agents. These compounds are kinase inhibitors, particularly inhibitors of spleen tyrosine kinase (SYK), and can be used to treat cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, and cardiovascular diseases.

The invention belongs to the field of nutrient substance research, and particularly relates to a nutrient composition for improving brain development. The nutritional composition provided by the invention comprises necessary active ingredients shown in the following (i) and (ii): (i) lactose-N-neotetraose, (ii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and (iii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine. The nutritional composition comprises lactose-N-neotetraose and 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine is 1: (0.010-2.5). The research shows that the combination of the lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine can be used for improving offspring brain immune disorder and / or nervous system dysplasia caused by maternal immune activation, and the lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine have a synergistic interaction effect.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The present disclosure provides compositions such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells that include and / or modulate the expression or activity of immunoregulatory-related proteins in various embodiments. The present disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infectious diseases, and / or immune disorders using agents that include and / or modulate the expression or activity of immunoregulatory-related proteins, as well as methods of identifying said agents.

The present invention refers to an oligonucleotide consisting of a core sequence of ATATTTAGGTCCAGCG (SEQ ID NO:1) or AATATTTAGGTCCAGCG (SEQ ID NO:2) and at least one additional nucleotide at the 3´-end and optionally at least one additional nucleotide at the 5´-end. At least one of the nucleotides of the oligonucleotide is modified, and the oligonucleotide binds to pre-mRNA of neuropilin 1 (NRP1, CD304). The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating cancer, an ophthalmic disease, an autoimmune disorder and / or an immune disorder.

A method and compositions of matter for treating or preventing an auto-immune disorder or immune response in a patient, that includes providing a therapeutic dose to the patient of a substituted indole compound having at least one substitution, wherein the substituted indole compound has only one thiol group, and wherein the ring the thiol group is attached to only contains one N or O atom.

Methods and compositions for cellular rejuvenation of immune cells, such as T cells, are provided. Cellular rejuvenation can be achieved by exposure, such as transient exposure, of immune cells to mRNAs encoding reprogramming factors. Compositions comprising such rejuvenated immune cells, including rejuvenated T cells, and uses of the rejuvenated immune cells in treating certain diseases and / or disorders, such as cancer and immune disorders, are also provided